Drugs / PF-07265028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05233436 | Feb 2022 → Oct 2023 | gastric cancer, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +1 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07265028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05233436 ↗ |
| Route | Oral | “PF-07265028 will be administered orally” NCT05233436 ↗ |